Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have received an average rating of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $18.80.

A number of equities analysts have issued reports on the company. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a report on Friday, August 9th. B. Riley reissued a “buy” rating and set a $20.00 target price on shares of Altimmune in a research note on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd.

Altimmune Stock Down 1.2 %

Shares of NASDAQ ALT opened at $6.72 on Thursday. The company has a market capitalization of $476.46 million, a PE ratio of -4.23 and a beta of 0.08. Altimmune has a twelve month low of $2.15 and a twelve month high of $14.84. The firm has a fifty day simple moving average of $6.74 and a 200 day simple moving average of $6.91.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The business had revenue of $0.01 million during the quarter. During the same period in the previous year, the business posted ($0.32) earnings per share. As a group, equities analysts expect that Altimmune will post -0.54 earnings per share for the current fiscal year.

Insider Activity at Altimmune

In related news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the sale, the director now owns 41,958 shares in the company, valued at $289,510.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. North Star Investment Management Corp. purchased a new position in Altimmune during the first quarter worth about $31,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of Altimmune in the 1st quarter worth approximately $44,000. TFO Wealth Partners LLC bought a new position in shares of Altimmune in the first quarter valued at approximately $51,000. Horizon Wealth Management LLC bought a new position in shares of Altimmune in the second quarter valued at approximately $66,000. Finally, PFG Investments LLC purchased a new stake in shares of Altimmune during the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.